Navigation Links
China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
Date:11/20/2008

new lung cancer cases were diagnosed each year in China and the incidence rate of lung cancer is expected to continue to increase.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit http://www.chinameditech.com .

    For more information, please contact:

     Winnie Yam
     Tel:   +86-10-6530-8833
     Email: IR@chinameditech.com

'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
2. China Biologic Products Reports Strong Third Quarter 2008 Results
3. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
4. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
5. China Biologic Products Announces Third Quarter 2008 Results Conference Call
6. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
7. China Clean Energy Resumes Biodiesel Production After Temporary Halt
8. China Medicine Announces Conference Call to Discuss Third Quarter 2008 Results
9. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2008 Results
11. China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... endpoint Clinical ( www.endpointclinical.com ), a ... (IWR) systems, announced today that PULSE, a fully ... deploy clinical trial Integrated Response Technology (IRT) systems, ... clinical trials. This time and cost savings stems ... developers do not have to spend valuable time ...
(Date:2/9/2010)... A leading clinical research center in ... study an investigational drug designed as a possible treatment ... affects between 45 and 90 percent of women of ... not life threatening, dysmenorrhea can be debilitating and psychologically ... absenteeism from work and school. ,, Current therapies for ...
(Date:2/9/2010)... BEACH, California and AMSTERDAM , ... in molecular cancer diagnostics, announced today that,it has ... New York State ,Department of Health. The ... to receive,commercial samples of MammaPrint, its FDA-cleared breast ... this latest permit, Agendia has now obtained all ...
(Date:2/9/2010)... February 9 ,, ... Microplasmin to Improve the Treatment,of a Range of ... ThromboGenics NV (Euronext Brussels: THR), a ... innovative treatments for eye,disease, vascular disease and cancer, ... results, evaluating the product,s efficacy and,safety in patients ...
Breaking Biology Technology:endpoint Saves Money and Time for Medical Research Teams Through PULSE 2endpoint Saves Money and Time for Medical Research Teams Through PULSE 3Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps 2Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 2ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 3ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology 4
... Training Center Scheduled to Open Friday, Feb. 29, ... Institute, LLC,will open its first training center in the ... local communities. Located in,Milipitas, CA, the center will be ... than 20 million Americans and costs the economy,$174 billion ...
... Continued year over year growth driven by Loestrin 24 ... Warner Chilcott,Limited (Nasdaq: WCRX ) today announced ... 2007. Revenue in the quarter ended December 31, 2007,totaled ... year quarter.,Revenue for the year ended December 31, 2007 ...
... today announced the submission of a supplemental New ... Administration (FDA) for once- daily,SEROQUEL XR(TM) (quetiapine fumarate) ... major depressive disorder (MDD) as,monotherapy, adjunct therapy, and ... 15 million American adults -- between 5 and ...
Other Biology Technology:MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 17AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 8
(Date:2/9/2010)... Miami have analyzed images based on Synthetic Aperture ... Haiti,s earthquake, on January 12. The images reveal ... using data from Japan,s ALOS satellite and made ... of the European Space Agency (ESA) and GEO, ... of countries that promotes the exchange of satellite ...
(Date:2/9/2010)... People with anorexia nervosa, paradoxically, have strikingly high levels ... Children,s Hospital Boston. Their findings, based on MRI imaging ... 20 healthy girls of the same age, appear in ... and Mineral Research . , "It,s counter-intuitive that an ... be storing fat in her marrow," says endocrinologist Catherine ...
(Date:2/9/2010)... The Scripps Research Institute have discovered a potential new ... for sheep and cattle infected with liver fluke. The ... in combating river blindness, a tropical disease that is ... humans. , The study is scheduled for publication ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):New international satellite observations help assess future earthquake risk in Haiti 2Anorexics found to have excess fat-- in their bone marrow 2Scripps research team reveals how an old drug could have a new use for treating river blindness 2Scripps research team reveals how an old drug could have a new use for treating river blindness 3Scripps research team reveals how an old drug could have a new use for treating river blindness 4GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 1GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 2GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 3GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 4New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 1New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 2New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 3New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 4Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 1Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 2
... prevent global warming, researchers and policymakers are exploring a ... carbon dioxide that reaches the atmosphere. One possible approach ... the source an electric power plant, for example ... theoretically promising, the technique has never been tested in ...
... or array that can quickly detect disorders such as Down ... effective tool in prenatal diagnosis in a series of 300 ... report that appears in the current issue of the journal ... led by Dr. Arthur Beaudet and Dr. Sau Wai Cheung ...
... properties of cancer cells are their ability to divide without ... establish new tumor sites. Now, researchers from the Mayo ... acts as a deadly master switch, both freeing cancer cells ... is potentially good news, say the researchers, who published their ...
Other Biology News:MIT: Safe storage of greenhouse-gas carbon dioxide 2Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 2Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 3
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Biology Products: